Register Login

ARDELYX, INC. (ARDX)

SymbolARDX
NameARDELYX, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address400 FIFTH AVENUE,SUITE 210, WALTHAM, Massachusetts, 02451, United States
Telephone+1 510 745-1700
Fax—
Email—
Websitehttps://www.ardelyx.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK—
Description

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Additional info from NASDAQ:
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

2026-04-23 12:01

Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

Read more
2026-04-22 17:05

New Form 3 - ARDELYX, INC. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0002127718-26-000002 <b>Size:</b> 514 KB

Read more
2026-04-17 20:04

Director RAAB MICHAEL 🟡 adjusted position in 41.7K shares (1 derivative) of ARDELYX, INC. (ARDX) at $6.29 Transaction Date: Apr 15, 2026 | Filing ID: 000008

Read more
2026-04-16 12:01

Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026

Read more
2026-04-03 17:17

New Form 3 - ARDELYX, INC. <b>Filed:</b> 2026-04-03 <b>AccNo:</b> 0002125089-26-000001 <b>Size:</b> 514 KB

Read more
2026-04-01 12:01

Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

Read more
2026-03-26 16:42

New Form SCHEDULE 13G/A - ARDELYX, INC. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000607 <b>Size:</b> 7 KB

Read more
2026-03-18 20:42

Director RAAB MICHAEL 🟡 adjusted position in 41.7K shares (1 derivative) of ARDELYX, INC. (ARDX) at $5.84 Transaction Date: Mar 16, 2026 | Filing ID: 000006

Read more
2026-03-09 20:05

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

Read more
2026-02-25 21:13

RAAB MICHAEL 🟡 adjusted position in 41.7K shares (1 derivative) of ARDELYX, INC. (ARDX) at $6.25 Transaction Date: Feb 24, 2026 | Filing ID: 000067

Read more